NEW YORK, Feb 15 – George Soros’ company Soros Fund Management reduced its holding in CuraGen but maintained its stake in CuraGen’s privately held subsidiary, 454, a CuraGen spokesman said Thursday.

“Soros unloaded literally all of his biotech holdings, and we were one that he maintained his position in,” a CuraGen spokesman said. “We saw this as a vote of confidence.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.